Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study.

Autor: Bader P; Goethe University, University Hospital, Department of Pediatrics, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Frankfurt, Germany., Pötschger U; St. Anna Children's Cancer Research Institute, Vienna, Austria., Dalle JH; Pediatric Hematology and Immunology Department, Robert Debré Hospital, Groupe Hospitalo-Universitaire Assistance Publique Hôpitaux de Paris (GHU AP-HP) Nord, Université Paris Cité, Paris, France., Moser LM; Goethe University, University Hospital, Department of Pediatrics, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Frankfurt, Germany., Balduzzi A; Università degli Studi di Milano-Fondazione, FONDAZIONE MONZA E BRIANZA PER IL BAMBINO E LA SUA MAMMA (MBBM), Department for Pediatric Hematology and Oncology, Monza, Italy., Ansari M; CANSEARCH Research Platform for Pediatric Oncology and Hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Switzerland.; Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, Switzerland., Buechner J; Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway., Güngör T; Department of Hematology/Oncology/Immunology, Gene Therapy, and Stem Cell Transplantation, University Children's Hospital Zürich, Eleonore Foundation & Children's Research Center, Zürich, Switzerland., Ifversen M; Copenhagen University Hospital Rigshospitalet, Department for Pediatric Hematology and Oncology, Copenhagen, Denmark., Krivan G; Pediatric Hematology and Stem Cell Transplantation Department, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary., Pichler H; St. Anna Children's Hospital, University Vienna, Vienna, Austria., Renard M; Department of Paediatric Oncology, University Hospital Leuven, Leuven, Belgium., Staciuk R; Hospital de Pediatría 'Prof. Dr. Juan P. Garrahan,' Buenos Aires, Buenos Aires, Argentina., Sedlacek P; Department of Pediatric Hematology and Oncology, Motol University Hospital, Prague, Czech Republic., Stein J; Schneider Children's Medical Center of Israel and Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel., Heusel JR; Goethe University, University Hospital, Department of Pediatrics, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Frankfurt, Germany., Truong T; Division of Pediatric Oncology and Cellular Therapy, Alberta Children's Hospital, Calgary, Alberta, Canada., Wachowiak J; Department of Pediatric Oncology, Hematology and Transplantology, Poznań University of Medical Sciences, Poznań, Poland., Yesilipek A; Medical Park Antalya Hospital, Antalya, Turkey., Locatelli F; Department of Pediatric Hematology and Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy., Peters C; St. Anna Children's Cancer Research Institute, Vienna, Austria.; St. Anna Children's Hospital, University Vienna, Vienna, Austria.

Publikováno v: Blood advances [Blood Adv] 2024 Jan 23; Vol. 8 (2), pp. 416-428.